APA (7th ed.) Citation

C, X., SY, W., M, N., KY, Y., XQ, H., S, Q., . . . QQ, C. (2026). TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: A multicentre, two-cohort, phase 2 trial. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-26-0347

Chicago Style (17th ed.) Citation

C, Xu, et al. "TQB2618 Plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicentre, Two-cohort, Phase 2 Trial." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 2026. https://doi.org/10.1158/1078-0432.CCR-26-0347.

MLA (9th ed.) Citation

C, Xu, et al. "TQB2618 Plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicentre, Two-cohort, Phase 2 Trial." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 2026, https://doi.org/10.1158/1078-0432.CCR-26-0347.